Retatrutide Trial Shows Excessive Weight Loss and High Dropout Rate

A clinical trial for Retatrutide, an experimental GLP-1/GIP/glucagon drug, revealed that some participants lost too much weight. At the highest dose level, 11% of participants dropped out due to severe side effects.

By Marina Galperina · The Verge · May 21, 2026, 18:53 UTC

Retatrutide Trial Shows Excessive Weight Loss and High Dropout Rate

Topics: GLP-1 drug Retatrutide trial side effects weight loss

Read the full article at The Verge

More World news

Thomson Reuters Executives to Present at TD Securities Technology Conference PR Newswire · November 12, 2026, 16:00 UTC
BHP to Restructure Australian Iron Ore Operations Amid Rising Costs Seeking Alpha · November 12, 2026, 15:59 UTC
Capri Investment Group and GRIT Chicago Unveil $10 Billion Bronzeville Lakefront Development Plan PR Newswire · November 12, 2026, 16:00 UTC
Whoop Launches 'Whoop Humans' Social Network to Enhance Health Data Sharing TechCrunch · November 12, 2026, 16:00 UTC
SchoolWise Partners Advises on Sale of Wyalusing Valley and Wysox Children's Centers PR Newswire · November 12, 2026, 15:57 UTC
Jensen Huang Resigns as Nvidia CEO Amid Personal Scandal and Leadership Crisis CNBC · November 12, 2026, 15:45 UTC
Keurig Dr Pepper Launches $2 Billion Equity Offering to Reduce Debt Ahead of Corporate Split Seeking Alpha · November 12, 2026, 15:51 UTC
Old National Bancorp Announces Quarterly Dividend of $0.4375 per Share Seeking Alpha · November 12, 2026, 15:53 UTC
Old National Bancorp Announces Quarterly Dividend of $0.4375 per Share Seeking Alpha · November 12, 2026, 15:53 UTC
Oman Investment Authority Signs Multi-Billion Dollar Investment Package with Chinese Partners PR Newswire · November 12, 2026, 15:52 UTC